safinamide has been researched along with flecainide in 1 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (flecainide) | Trials (flecainide) | Recent Studies (post-2010) (flecainide) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 1,881 | 229 | 490 |
| Protein | Taxonomy | safinamide (IC50) | flecainide (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.8905 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bechtold, D; Chauhdry, S; Hassoon, P; Lee, W; Malpass, K; Morsali, D; Palchaudhuri, U; Piers, T; Pocock, J; Roach, A; Smith, KJ; Snell, DM | 1 |
1 other study(ies) available for safinamide and flecainide
| Article | Year |
|---|---|
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Topics: Alanine; Animals; Benzylamines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Flecainide; Male; Microglia; Multiple Sclerosis; Neuroprotective Agents; Rats; Sodium Channel Blockers | 2013 |